ENTPD5 not only hydrolyzes ATP but also interacts with fibroblast growth factor 23 and sodium‐dependent phosphate transporter 2a, participating in biological processes like bone metabolism.[36] Our study demonstrated that inhibition of hepatic ENTPD5 played important roles in triggering the development and progression of obesity and metabolic disorders. This evidence concerns the gene ENTPD5 and Other metabolic disease.